Comparison of Conventional and Cooled Radiofrequency of the Genicular Nerves in Patients With Chronic Knee Pain

Knee Osteoarthritis Clinical Trial

— COGENIUS  

Official title:

Comparison of Conventional and Cooled Radiofrequency Treatment of the Genicular Nerves Versus Sham Procedure for Patients With Chronic Knee Pain: a Multicentre, Double Blind, Randomised Controlled Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05407610
• Other study ID #: COGENIUS
• Secondary ID: Z-2021109KCE20-1
• Status: Recruiting
• Phase: N/A
• Start date: July 7, 2022
• Est. completion date: September 1, 2026

Study information

• Verified date: May 2023
• Source: Ziekenhuis Oost-Limburg
• Contact: Jan Van Zundert
• Phone: +32 (0)89 32.52.54
• Email: cogenius[@]zol.be
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Chronic knee pain remains a disabling disease despite current treatment strategies. There is an increase in the prevalence of osteoarthritis (OA) of the knee in the general population, presently affecting approximately 450,000 individuals in Belgium. A total knee replacement is a viable alternative for severe knee OA that does not respond to conservative therapy. Unfortunately, up to 53% of patients who undergo a total knee replacement develop persistent post-surgical pain (PPSP). There is currently no effective therapy for PPSP.

A radiofrequency (RF) treatment applies high frequency current on the nerve responsible for pain conduction, resulting in an interruption of the transmission of pain. This can be applied to the nerves innervating the knee joint - the superolateral, superomedial and inferomedial genicular nerves - and could be an alternative, minimally invasive treatment for patients with knee OA who fail conservative treatments and for patients with PPSP. Data from the recent literature indicates that this treatment leads to a reduction of pain intensity and could result in an improvement of knee function, of the psychological state of the individual, and finally in an increase in health-related quality of life. Furthermore, RF of the genicular nerves could help avoid or delay a total knee replacement therefore potentially contributing to cost reduction. Both cooled and conventional RF treatments are reported in the literature to improve pain. The use of water to cool the RF electrodes results in an increased lesion size by removing heat from adjacent tissue, allowing power delivery to be increased. As a consequence, cooled RF could result in a higher chance of success and longer duration of effect. Until now, the studies performed on cooled RF are industry initiated and a direct comparison between conventional, cooled and a sham procedure is lacking.

The aim of the COGENIUS trial is to investigate the effect of the two types of RF treatment on individuals experiencing chronic knee pain that is resistant to conservative treatments. For this purpose, the efficacy and cost-effectiveness of cooled and conventional RF will be compared to a sham procedure in patients suffering from knee OA and PPSP after total knee replacement.

Description:

In this three-arm, pragmatic, prospective, multicentre, double blind, randomised sham-controlled trial of approximately 4 years duration, 400 patients with chronic moderate to severe anterior knee pain (>12 months) refractory to conventional treatments will be included. Two groups of chronic knee pain patients will be enrolled depending on the aetiology of knee pain: OA and PPSP. Each patient will undergo a run-in period of 1 to 3 months depending on the previous treatments of the patient. A run-in period is added to the trial to guarantee that conservative treatment is performed in an optimal way before randomisation. In each group (osteoarthritis and persistent post-surgical pain), non-responders to the run-in period will be randomly allocated to a conventional RF intervention of the genicular nerves, a cooled RF intervention of the genicular nerves or a sham procedure in a 2:2:1 ratio. The patients will be followed up for a period of 2 years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 400
• Est. completion date: September 1, 2026
• Est. primary completion date: March 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed written informed consent must be obtained before any study assessment is performed.

• Adult patients (Age = 18 years old).

• Chronic anterior knee pain (> 12 months) that is moderate to severe (defined as NRS > 4 on most or all days for the index knee either constantly or with motion at time of screening and, an average NRS score reported in the patient diary >4 at the end of the run-in period).

• Unresponsive (meaning insufficient pain reduction or intolerance) to conventional treatments ongoing for at least 12 months prior to inclusion. Conventional treatments must include all of the following: active physiotherapy, pharmacological treatment of pain and intra-articular corticosteroid infiltration.

• Only for patients with Osteoarthritis (OA): Radiologic confirmation of knee osteoarthritis of grade 2 (mild), 3 (moderate) or 4 (severe) noted within 12 months prior to the screening for the index knee according the Kellgren Lawrence criteria diagnosed by an independent radiologist with experience in musculoskeletal imaging on radiography (Rx) or magnetic resonance imaging (MRI). If imaging will need to be performed at screening it is recommended to perform an MRI instead of Rx. Imaging with MRI will enable the independent radiologist to perform a better estimation of the grade of OA.

• Only for patients with Persistent Post-Surgical Pain (PPSP) after Total Knee Arthroplasty (TKA): Patients with PPSP* after TKA need to have had a negative orthopaedic work-up

Exclusion Criteria:

• Local or systemic infection (bacteraemia).

• Evidence of inflammatory arthritis or an inflammatory systemic disease responsible for knee pain.

• Intra-articular injections (steroids, hyaluronic acid, platelet enriched plasma, ...) in the index knee during the 3 months prior to procedure.

• Pregnant, nursing or planning to become pregnant before the study intervention. Participants who become pregnant after the study intervention during the follow-up period will not be excluded.

• Chronic widespread pain.

• Patients with unstable psychosocial disorder.

• Allergies to products used during the procedure (lidocaine, propofol, chlorhexidine).

• Uncontrolled coagulopathy defined as supratherapeutic dose of anticoagulation medication.

• Uncontrolled immune suppression.

• Participating in another clinical trial/investigation within 30 days prior to signing informed consent.

• Patient is currently implanted with a neurostimulator.

• Current radicular pain in index leg.

• Previous conventional or cooled radiofrequency of the index knee.

• Patients with bilateral knee pain defined as chronic knee pain (> 12 months) in both knees that is moderate to severe (defined as a numeric rating scale (NRS) > 4 on most or all days either constantly or with motion) and that is unresponsive (meaning insufficient pain reduction or intolerance) to conventional treatments ongoing for at least 12 months prior to inclusion. Conventional treatments must include all of the following: active physiotherapy, pharmacological treatment of pain and intra-articular corticosteroid infiltration.

• Patients who have a planned TKA in the near future defined as patients who already have agreed on a date for the TKA procedure.

• Patients who are unwilling or mentally incapable to complete the study questionnaires.

Related Conditions & MeSH terms

• Chronic Knee Pain
• Knee Osteoarthritis
• Osteoarthritis
• Osteoarthritis, Knee
• Pain, Postoperative
• Persistent Postsurgical Pain

Intervention

Procedure:
• Conventional Radiofrequency ablation of the genicular nerves
Conventional Radiofrequency treatment of the genicular nerves of the knee blocks the transmission of painful stimuli from the sensory genicular nerves of the knee to the central nervous system by means of a thermal lesion created using RF current.
• Cooled Radiofrequency ablation of the genicular nerves
Cooled RF treatment causes a larger lesion size compared to conventional RF by means of internal cooling of the probe.
• Sham procedure
Sham procedure with placing of needles subcutaneously.

Locations

Country	Name	City	State
Belgium	UZ Antwerpen	Antwerpen
Belgium	AZ Klina	Brasschaat
Belgium	UCL Saint-Luc	Brussel
Belgium	ULB Erasme	Brussel
Belgium	Ziekenhuis Oost-Limburg AV	Genk
Belgium	AZ Maria Middelares	Gent
Belgium	Jessa Ziekenhuis	Hasselt
Belgium	AZ Groeninge	Kortrijk
Belgium	UZ Leuven	Leuven
Belgium	CHR de la Citadelle	Liège
Belgium	CHU Liège	Liège
Belgium	AZ Delta	Roeselare
Belgium	AZ Turnhout	Turnhout
Netherlands	Rijnstate	Arnhem
Netherlands	MUMC	Maastricht

Sponsors (3)

Lead Sponsor	Collaborator
Ziekenhuis Oost-Limburg	Belgium Health Care Knowledge Centre, Klinische Epidemiologie en Medical Technology Assessment

Countries where clinical trial is conducted

Belgium,  Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Phenotype of patients suffering from Persistent Post-Surgical Pain (PPSP)	Demographic data collected at baseline will be used to phenotype patients suffering from PPSP.	Baseline
Other	Time to additional interventions	Time to additional interventions at each time point. Interventions will be divided in minimally invasive interventions (intraarticular (IA) steroid injections, IA hyaluronic acid, platelet rich plasma of infiltrations, repeat RF of the genicular nerves) and surgery (primary/revision total knee arthroplasty and other knee related surgery) during the follow-up.	Follow-up until 24-months post- intervention.
Primary	The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at 6 months post-intervention	The primary endpoint is the WOMAC score (range 0-96) at 6 months post-intervention.; The WOMAC score is derived from a self-administered osteoarthritis-specific validated questionnaire on pain, stiffness, and physical functioning of the knee joint.The lower the score, the lower the osteoarthritis-specific symptoms are.	6 months post-intervention.
Secondary	The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score.	The WOMAC score (range 0-96) is derived from a self-administered osteoarthritis-specific validated questionnaire on pain, stiffness, and physical functioning of the knee joint.The lower the score, the lower the osteoarthritis-specific symptoms are.	1-, 3-, 6-, 12- and 24-months post-intervention.
Secondary	Pain Intentisty	Pain intensity expressed by the Numerical Rating Scale (NRS) (range 0-10). The NRS score at each visit will be calculated as the mean score of the 4 days prior to each visit.The lower the score, the least pain the patient experiences.	1-, 3-, 6-, 12- and 24-months post-intervention.
Secondary	The proportion of patients with a pain reduction of at least 50% compared to baseline expressed by the numerical rating scale (NRS)	The proportion of patients with a pain reduction of at least 50% compared to baseline expressed by the numerical rating scale (NRS) (0-10). The NRS score at each visit will be calculated as the mean score of the 4 days prior to each visit.The lower the score, the least pain the patient experiences.	1-, 3-, 6-, 12- and 24-months post-intervention.
Secondary	Health-related quality of life	Health-related quality of life assessed by the EuroQoL-5D-5L (EQ-5D-5L). The questionnaire consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression and a visual assessment scale. Responses to the 5 items (one for each dimension) result in a patient's health state that can be transformed into a utility score ranging between 0 (death) and 1 (full health), representing the quality of life of the health state. For the visual assessment scale section, the patient indicates their impression of health on the visual scale. The scale has the following distribution: 0 indicating "worse possible health" and 100 indicating "best possible health".	1-, 3-, 6-, 9-, 12- and 24-months post-intervention.
Secondary	Goniometry	Goniometry (maximal knee flexion and extension expressed in degrees) is assessed using the CJOrtho app. The degrees range from 0 to 180 degrees.	1-, 3-, 6-, 12- and 24-months post-intervention.
Secondary	'Timed up and Go' test	The 'Timed up and Go' test assesses the physical functioning of the patient.	1-, 3-, 6-, 12- and 24-months post-intervention.
Secondary	The 6-minute walk test	The 6-minute walk test assesses the physical functioning of the patient. The distance in meters covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.	1-, 3-, 6-, 12- and 24-months post-intervention.
Secondary	The Hospital Anxiety and Depression Scale (HADS)	The Hospital Anxiety and Depression Scale (HADS) assesses and detect anxiety and depression in patients with physical health problems. The questionnaire consists of 14 items: 7 items to measure anxiety and 7 items to measure depression.	1-, 3-, 6-, 12- and 24-months post- intervention.
Secondary	The Pain Catastrophizing Scale (PCS)	The Pain Catastrophizing Scale (PCS) assesses the mental health of the patient.The 13 item questionnaire consists of 3 subscales (magnification, rumination and helplessness) and asks patients to reflect on past painful experiences and to indicate the degree on which they experiences each of 13 thoughts of feelings on a 5- point scale (0 not at all and 4 all the time).	1-, 3-, 6-, 12- and 24-months post- intervention.
Secondary	Patient Global Impression of Change (PGIC)	Patients' Patient's Global Impression of Change (PGIC) scale is a self-reported measure that reflects the patient's belief about the treatment efficacy. The patient is asked to rate the efficacy of the treatment on a scale of 1 (much better) to 7 (much worse).	1-, 3-, 6-, 12- and 24-months post- intervention.
Secondary	Patient's satisfaction	Patient's satisfaction assessed by 7-point Likert scale with 0 representing total dissatisfaction and 10 representing maximal satisfaction.	1-, 3-, 6-, 12- and 24-months post- intervention.
Secondary	Medication use	Medication use measured by Medication Quantification Scale III (MQS III).It computes a single numeric value for a patient's pain medication profile. This number is used to track pain levels through a treatment course or research study.	1-, 3-, 6-, 9-, 12- and 24-months post- intervention.
Secondary	Opioid dependence	The patient is strong opioid dependent if the patient takes an opioid analgesic with the exception of analgesics with tramadol or codeine.	1-, 3-, 6-, 9-, 12- and 24-months post- intervention.
Secondary	Incidence of related adverse events	The incidence of related adverse events. Active capture during each study contact to assess specific symptoms and adverse events relevant to chronic knee pain or RF intervention.	Follow-up until 24-months post- intervention.
Secondary	Health care resource utilisation	The health care resource use questions are created for the COGENIUS study to collect information regarding the visits to a medical specialist (doctor or nurse) or general practitioner as a result of knee pain.	Follow-up until 24-months post- intervention.
Secondary	Productivity loss due to sickness	Productivity loss due to sickness assessed by the Work Productivity and Activity Impairment (WPAI). Productivity loss due to sickness refers to output loss resulting from work absence and/or reduced labour input due to sickness. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes.	Follow-up until 24-months post- intervention.